Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study

Christopher Tehlirian, Elena Peeva, Elizabeth Kieras, Matthew Scaramozza, Erika Roberts, Ravi Shankar Prasad Singh, Vivek Pradhan, Anindita Banerjee, Sandra Garcet, Xi Li, Jeremy D. Gale, Michael S. Vincent, James G. Krueger